Consistent with this possible linkage between FOXC1, the AKT pathway, and cisplatin resistance of SP cells, we have previously shown that an AKT inhibitor can reduce the transition to the SP phenotype and decrease cisplatin resistance in bladder cancer [5]. This evidence concerns the gene FOXC1 and urinary bladder cancer.